Radicle Revive 24: A Study of Health and Wellness Products on Menopausal Health and Related Health Outcomes

Last updated: July 2, 2025
Sponsor: Radicle Science
Overall Status: Completed

Phase

N/A

Condition

Depression

Insomnia

Menopause

Treatment

Radicle Revive Placebo Control Form 4.1

Radicle Revive Active Study Product 4.1 Usage

Clinical Study ID

NCT06749288
RADX-P-2414
  • Ages 21-105
  • Female
  • Accepts Healthy Volunteers

Study Summary

A randomized, double-blind, placebo-controlled, direct-to-consumer trial assessing the impact of health and wellness products on hormonal health and associated health outcomes in women with menopausal health issues

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adults, 21 years of age and older at the time of electronic consent, inclusive ofall ethnicities, races, genders and/or gender identities

  • Resides in the United States

  • Endorses less pain as a primary desire

  • Selects pain and/or looking to improve their pain as a reason for their interest intaking a health and wellness product

  • Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study

Exclusion

Exclusion Criteria:

  • reports being pregnant, trying to become pregnant, or breastfeeding

  • Unable to provide a valid US shipping address and mobile phone number

  • The calculated validated health survey (PRO) score during enrollment represents lessthan mild severity

  • Reports a diagnosis of liver or kidney disease

  • Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages perday)

  • Unable to read and understand English

  • Reports current enrollment in a clinical trial

  • Lack of reliable daily access to the internet

  • Reports current or recent (within 3 months) use of chemotherapy or immunotherapy

  • Reports taking medications with a known moderate or severe interaction with any ofthe active ingredients studied, or a substantial safety risk: Anticoagulants, amedication that warns against grapefruit consumption, corticosteroids at dosesgreater than 5 mgs per day, oral anti-infectives (antibiotics, antifungals,antivirals) to treat an acute infection, antipsychotics, or MAO

Study Design

Total Participants: 500
Treatment Group(s): 2
Primary Treatment: Radicle Revive Placebo Control Form 4.1
Phase:
Study Start date:
January 01, 2025
Estimated Completion Date:
July 01, 2025

Study Description

This is a randomized, double-blind, placebo-controlled study conducted with adult participants, residing in the United States.

Eligible participants (1) are females, (2) have menopausal health issues for 3 months or longer, (3) have the opportunity to improve by at least 30%, and (4) express acceptance in taking study products and not knowing the formulation identities until the end of the study.

Participants that report a known cardiac dysfunction, liver or kidney disease may be excluded. Participants that report a known contraindication or with well-established, significant safety concerns due to illness will be excluded. Heavy drinkers and women who are pregnant or breastfeeding will be excluded. Participants that report taking medications with a known contraindication or with well-established, significant safety concerns will be excluded.

Self-reported data are collected electronically from eligible participants for 7 weeks. Participant reports of health indicators will be collected at baseline, throughout the active period of study product use, and in a final survey. All study assessments will be electronic; there are no in-person visits or assessments for this real-world evidence study.

Connect with a study center

  • Radicle Science, Inc

    Del Mar, California 92014
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.